Induction of malformations in the cynomolgus monkey with 13‐cis retinoic acid

Hans Hummler, Rainhart Korte, Andrew G Hendrickx

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The embryotoxic and teratogenic potential of 13‐cis retinoic acid was assessed in the cynomolgus macaque (Macaca fascicularis). A total of 41 animals was orally administered 13‐cis retinoic acid in four sequential experiments. In Exp. 1 three dose levels, 2, 10, and 25 mg/kg, were administered on gestational day (GD) 18–28; 5 mg/kg was administered as an equally divided dose twice daily in Exp. 2 and 3 on GD 21–24 and on GD 25–27, respectively; in Exp. 4 the drug was administered at 2.5 mg/kg once daily from GD 10 to 25 and twice daily (2 × 2.5 mg/kg) on GD 26 and 27. Maternal death and toxicity, manifested as reduction in maternal weight and food consumption, and diarrhea, was observed in Exp. 1 in all three dose groups. No significant maternal toxicity was observed in the treatment groups in Exp. 2, 3, and 4 or in the control group. The primary manifestation of developmental toxicity was embryolethality in Exp. 1 and 2. The incidence of embryonic deaths in Exp. 3 was comparable to the historical controls. No malformations in GD 100 fetuses were observed in Exp. 1, 2, and 3. In Exp. 4, five of seven fetuses (71%) had malformations of both external ears, four of seven fetuses (57%) exhibited hypo‐ or aplasia of the thymus, and two of seven (29%) had malformations (transposition of the great vessels, ventricular septal defect) of the heart. The teratogenic dose for the cynomolgus monkey in the present study was lower than that reported for all other experimental species. Although central nervous system and craniofacial defects were not observed, the incidence of ear and thymus defects was similar to that reported for the human. The cardiovascular defects resembled those reported clinically, but the incidence was lower in the cynomolgus monkey. The similarity in teratogenic sensitivity to humans supports the use of the monkey as a model for developmental toxicity studies of vitamin A‐related compounds.

Original languageEnglish (US)
Pages (from-to)263-272
Number of pages10
JournalTeratology
Volume42
Issue number3
DOIs
StatePublished - 1990

Fingerprint

Macaca fascicularis
Tretinoin
Toxicity
Fetus
Thymus
Thymus Gland
Defects
Incidence
Mothers
External Ear
Maternal Death
Transposition of Great Vessels
Ventricular Heart Septal Defects
Macaca
Vitamins
Haplorhini
Ear
Diarrhea
Neurology
Central Nervous System

ASJC Scopus subject areas

  • Embryology
  • Toxicology
  • Developmental Biology
  • Health, Toxicology and Mutagenesis

Cite this

Induction of malformations in the cynomolgus monkey with 13‐cis retinoic acid. / Hummler, Hans; Korte, Rainhart; Hendrickx, Andrew G.

In: Teratology, Vol. 42, No. 3, 1990, p. 263-272.

Research output: Contribution to journalArticle

Hummler, Hans ; Korte, Rainhart ; Hendrickx, Andrew G. / Induction of malformations in the cynomolgus monkey with 13‐cis retinoic acid. In: Teratology. 1990 ; Vol. 42, No. 3. pp. 263-272.
@article{a3ec72d6a43c4dbe9478e2e714797358,
title = "Induction of malformations in the cynomolgus monkey with 13‐cis retinoic acid",
abstract = "The embryotoxic and teratogenic potential of 13‐cis retinoic acid was assessed in the cynomolgus macaque (Macaca fascicularis). A total of 41 animals was orally administered 13‐cis retinoic acid in four sequential experiments. In Exp. 1 three dose levels, 2, 10, and 25 mg/kg, were administered on gestational day (GD) 18–28; 5 mg/kg was administered as an equally divided dose twice daily in Exp. 2 and 3 on GD 21–24 and on GD 25–27, respectively; in Exp. 4 the drug was administered at 2.5 mg/kg once daily from GD 10 to 25 and twice daily (2 × 2.5 mg/kg) on GD 26 and 27. Maternal death and toxicity, manifested as reduction in maternal weight and food consumption, and diarrhea, was observed in Exp. 1 in all three dose groups. No significant maternal toxicity was observed in the treatment groups in Exp. 2, 3, and 4 or in the control group. The primary manifestation of developmental toxicity was embryolethality in Exp. 1 and 2. The incidence of embryonic deaths in Exp. 3 was comparable to the historical controls. No malformations in GD 100 fetuses were observed in Exp. 1, 2, and 3. In Exp. 4, five of seven fetuses (71{\%}) had malformations of both external ears, four of seven fetuses (57{\%}) exhibited hypo‐ or aplasia of the thymus, and two of seven (29{\%}) had malformations (transposition of the great vessels, ventricular septal defect) of the heart. The teratogenic dose for the cynomolgus monkey in the present study was lower than that reported for all other experimental species. Although central nervous system and craniofacial defects were not observed, the incidence of ear and thymus defects was similar to that reported for the human. The cardiovascular defects resembled those reported clinically, but the incidence was lower in the cynomolgus monkey. The similarity in teratogenic sensitivity to humans supports the use of the monkey as a model for developmental toxicity studies of vitamin A‐related compounds.",
author = "Hans Hummler and Rainhart Korte and Hendrickx, {Andrew G}",
year = "1990",
doi = "10.1002/tera.1420420310",
language = "English (US)",
volume = "42",
pages = "263--272",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Induction of malformations in the cynomolgus monkey with 13‐cis retinoic acid

AU - Hummler, Hans

AU - Korte, Rainhart

AU - Hendrickx, Andrew G

PY - 1990

Y1 - 1990

N2 - The embryotoxic and teratogenic potential of 13‐cis retinoic acid was assessed in the cynomolgus macaque (Macaca fascicularis). A total of 41 animals was orally administered 13‐cis retinoic acid in four sequential experiments. In Exp. 1 three dose levels, 2, 10, and 25 mg/kg, were administered on gestational day (GD) 18–28; 5 mg/kg was administered as an equally divided dose twice daily in Exp. 2 and 3 on GD 21–24 and on GD 25–27, respectively; in Exp. 4 the drug was administered at 2.5 mg/kg once daily from GD 10 to 25 and twice daily (2 × 2.5 mg/kg) on GD 26 and 27. Maternal death and toxicity, manifested as reduction in maternal weight and food consumption, and diarrhea, was observed in Exp. 1 in all three dose groups. No significant maternal toxicity was observed in the treatment groups in Exp. 2, 3, and 4 or in the control group. The primary manifestation of developmental toxicity was embryolethality in Exp. 1 and 2. The incidence of embryonic deaths in Exp. 3 was comparable to the historical controls. No malformations in GD 100 fetuses were observed in Exp. 1, 2, and 3. In Exp. 4, five of seven fetuses (71%) had malformations of both external ears, four of seven fetuses (57%) exhibited hypo‐ or aplasia of the thymus, and two of seven (29%) had malformations (transposition of the great vessels, ventricular septal defect) of the heart. The teratogenic dose for the cynomolgus monkey in the present study was lower than that reported for all other experimental species. Although central nervous system and craniofacial defects were not observed, the incidence of ear and thymus defects was similar to that reported for the human. The cardiovascular defects resembled those reported clinically, but the incidence was lower in the cynomolgus monkey. The similarity in teratogenic sensitivity to humans supports the use of the monkey as a model for developmental toxicity studies of vitamin A‐related compounds.

AB - The embryotoxic and teratogenic potential of 13‐cis retinoic acid was assessed in the cynomolgus macaque (Macaca fascicularis). A total of 41 animals was orally administered 13‐cis retinoic acid in four sequential experiments. In Exp. 1 three dose levels, 2, 10, and 25 mg/kg, were administered on gestational day (GD) 18–28; 5 mg/kg was administered as an equally divided dose twice daily in Exp. 2 and 3 on GD 21–24 and on GD 25–27, respectively; in Exp. 4 the drug was administered at 2.5 mg/kg once daily from GD 10 to 25 and twice daily (2 × 2.5 mg/kg) on GD 26 and 27. Maternal death and toxicity, manifested as reduction in maternal weight and food consumption, and diarrhea, was observed in Exp. 1 in all three dose groups. No significant maternal toxicity was observed in the treatment groups in Exp. 2, 3, and 4 or in the control group. The primary manifestation of developmental toxicity was embryolethality in Exp. 1 and 2. The incidence of embryonic deaths in Exp. 3 was comparable to the historical controls. No malformations in GD 100 fetuses were observed in Exp. 1, 2, and 3. In Exp. 4, five of seven fetuses (71%) had malformations of both external ears, four of seven fetuses (57%) exhibited hypo‐ or aplasia of the thymus, and two of seven (29%) had malformations (transposition of the great vessels, ventricular septal defect) of the heart. The teratogenic dose for the cynomolgus monkey in the present study was lower than that reported for all other experimental species. Although central nervous system and craniofacial defects were not observed, the incidence of ear and thymus defects was similar to that reported for the human. The cardiovascular defects resembled those reported clinically, but the incidence was lower in the cynomolgus monkey. The similarity in teratogenic sensitivity to humans supports the use of the monkey as a model for developmental toxicity studies of vitamin A‐related compounds.

UR - http://www.scopus.com/inward/record.url?scp=0025042656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025042656&partnerID=8YFLogxK

U2 - 10.1002/tera.1420420310

DO - 10.1002/tera.1420420310

M3 - Article

C2 - 2274892

AN - SCOPUS:0025042656

VL - 42

SP - 263

EP - 272

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 3

ER -